Table of Contents Table of Contents
Previous Page  10 / 32 Next Page
Information
Show Menu
Previous Page 10 / 32 Next Page
Page Background

Motzer RJ. N Engl J Med 2013;369(8):722.

Instrument

Domain Description

Treatment difference : mean change

from baseline

2

P -value

FACIT-F

Fatigue/Total score

2.32

<0.001

FKSI-19

Kidney Symptom Index/Total score

1.41

0.018

Physical

0.78

0.027

Emotional

0.05

0.409

Treatment Side Effects

0.31

0.033

Functional Well Being

0.31

0.098

Cancer Treatment

Satisfaction

Questionnaire (CTSQ)

Expectations of Therapy

1.41

0.284

Feelings about Side Effects

8.50

<0.001

Satisfaction with Therapy

3.21

<0.001

SupplementaryQuality

of Life Questionnaire

(SQLQ)

Worst mouth/throat soreness

0.505

<0.0001

Worst foot soreness

0.204

0.0016

Worst hand soreness

0.267

0.0008

Limitations due to mouth/throat soreness

0.94

<0.001

Limitations due to foot soreness

0.65

0.014

Pazopanib

Pazopanib

COMPARZ: fase III.

PAZOPANIB: ENSAYOS CLÍNICOS.